Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
US8455629B2 · kind B2 · utility
0Cited by
90References
18Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jan 27, 2012 |
| Grant date | Jun 4, 2013 |
| Priority date | — |
| Expiry date | Feb 13, 2032 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/56
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Monoclonal antibodies and hybridomas producing them that interact with osteoprotegerin ligand (OPGL) are provided. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are also provided. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are further provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.